MADRIGAL PHARMACEUTICALS, INC.

Pharmaceutical Preparations

MDGL Pharmaceuticals & Biotechnology People in Pharmaceuticals & Biotechnology SEC CIK 0001157601 ↗

Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.

Market capitalisation
$12.35B
23,104,126 shares Covers every share class this company has on file.
Insiders on file
15
people who have filed Form 3, 4 or 5 naming this issuer
Value of insider-held stock
$1.40B
from the holdings reported on Forms 3/4/5; this figure has no separate as-of date on file
Insider-held share of market cap
11.34%
insider-held value divided by market capitalisation

What MADRIGAL PHARMACEUTICALS, INC. reports

Revenue and net income below are for fiscal period FY2025, the period label carried by this company’s own annual XBRL filings to the SEC. Fiscal years do not line up between companies — one company’s FY2026 can cover much the same months as another’s FY2025 — so compare the periods, not just the numbers.

Revenue
$958.40M
FY2025 annual revenue, from this company’s own annual XBRL filings to the SEC
Net income
-$288.28M
FY2025 a loss for the period, from this company’s own annual XBRL filings to the SEC
Employees
915
Yahoo Finance
Where the employee count comes from

Headcount comes from Yahoo Finance, not from a filing. The date beside it is the day we retrieved the figure — it is not the date the company counted its staff, and Yahoo does not publish that date. Unlike the SEC filings behind the other figures on this page, this one carries no open licence, so we publish the number and nothing else from that source.

Insiders at MADRIGAL PHARMACEUTICALS, INC.

Shares is what each person last reported holding here.

Everyone below has filed at least one insider report against this company.

Value is that share count priced at the same closing price used everywhere else on this site. A row priced from only some of a person’s securities says so — we do not quietly present a partial sum as a complete one.

Rows are grouped by the role each person reports.

The role comes from the relationship boxes a person ticks on their own insider filings — officer, director, ten per cent owner — not from anything we infer. Somebody who is both an officer and a director appears once, in the combined group, so the row count still matches the figure at the top of this page. Where no filing states a role we say so instead of guessing one.

People who file insider reports against MADRIGAL PHARMACEUTICALS, INC..
Insider Reported role Shares Value Last action
Officers 5
Carole Huntsman Other Executive 12,692 $6.87M S Open-market sale Mar 6, 2026 position reported
Shannon T Kelley General Counsel 12,138 $6.57M S Open-market sale Aug 17, 2026 position reported
David Soergel Other Executive 11,919 $6.45M S Open-market sale Jun 1, 2026 position reported
Robert E Waltermire SVP 5,789 $3.13M — position reported
Rita Thakkar Chief Accounting Officer 2,398 $1.30M A Grant or award Jan 15, 2026 position reported
Officers who also sit on the board 4
Rebecca Taub President 1,107,753 $599.38M A Grant or award Jun 17, 2026 position reported
William John Sibold CEO 161,829 $87.56M S Open-market sale Sep 11, 2026 position reported
Mardi Dier CFO 12,490 $6.76M S Open-market sale Mar 6, 2026 position reported
Daniel J Brennan CFO 967 $523.2K A Grant or award Jun 17, 2026 position reported
Directors 6
Paul A. Friedman Board Member 842,704 $455.97M S Open-market sale Jan 9, 2026 position reported
Fred B. Craves Board Member 382,286 $206.85M — position reported
Richard S Levy Board Member 27,697 $14.99M A Grant or award Jun 17, 2026 position reported
James M Daly Board Member 2,627 $1.42M A Grant or award Jun 17, 2026 position reported
Kenneth Bate Board Member 2,627 $1.42M — position reported
Jacqualyn A. Fouse Board Member 1,097 $593.6K A Grant or award Jun 17, 2026 position reported

Events from filings

Detected automatically in the filings linked below. Each headline is built from the numbers in those filings, not written by a model. Newest first; events older than 45 days stay listed and are marked as older.

MADRIGAL PHARMACEUTICALS, INC. (MDGL) filed a Form 8-K under Item 5.02 (directors and officers) on Aug 12, 2026

Director or officer change filing

The company filed a current report that includes Item 5.02, the item used to report departures, elections or appointments of directors and certain officers, and related pay arrangements. We record only that this filing exists: we have not extracted who left, who joined or whose role changed. Open the filing to read it.

Form 8-K filed Aug 12, 2026, items 5.02, 7.01, 9.01. SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Paul A. Friedman sold 28,976 MADRIGAL PHARMACEUTICALS, INC. (MDGL) shares for $10,790,373 on Aug 13, 2025

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Paul A. Friedman sold 28,976 MADRIGAL PHARMACEUTICALS, INC. (MDGL) shares for $10,790,373 on Aug 13, 2025
Date Insider Transaction Shares Price Value Filing
Aug 13, 2025 Paul A. Friedman S Open-market sale 28,976 held after: 215,485 $372.39 $10,790,373 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

James M Daly sold 14,302 MADRIGAL PHARMACEUTICALS, INC. (MDGL) shares for $4,968,372 on Feb 27, 2025

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

James M Daly sold 14,302 MADRIGAL PHARMACEUTICALS, INC. (MDGL) shares for $4,968,372 on Feb 27, 2025
Date Insider Transaction Shares Price Value Filing
Feb 27, 2025 James M Daly S Open-market sale 14,302 held after: 2,682 $347.39 $4,968,372 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Kenneth Bate sold 8,545 MADRIGAL PHARMACEUTICALS, INC. (MDGL) shares for $3,034,159 on Feb 27, 2025

Large trade for this person

Flagged because this trade was large compared with this person’s own earlier open-market trades in the same currency — not because it is large in absolute terms. A trade that is routine for one insider can be flagged for another.

Kenneth Bate sold 8,545 MADRIGAL PHARMACEUTICALS, INC. (MDGL) shares for $3,034,159 on Feb 27, 2025
Date Insider Transaction Shares Price Value Filing
Feb 27, 2025 Kenneth Bate S Open-market sale 8,545 held after: 12,529 $355.08 $3,034,159 SEC filing ↗

Source: SEC EDGAR (United States); every row links to where it was published. Event computed Sep 14, 2026.

Recent insider transactions

Of the 550 rows we hold, 0 are open-market purchases and 451 open-market sales (S) — the only codes we count as buying or selling.

The rest — awards, shares withheld to pay tax, option exercises, gifts and so on — follow from an employment contract or a transfer arranged off-market, not from a decision to buy or sell, so counting them would turn this into a pay table.

A price of 0.00 is a real reported figure on gifts (G) and share awards (A) — not a gap in our data.

Insider transactions disclosed to the SEC for MADRIGAL PHARMACEUTICALS, INC., newest first, each with the filing behind it.
Date Insider Transaction Shares Price Value Filing
Sep 11, 2026 William John Sibold S Open-market sale 120 $546.38 $65.6K SEC filing ↗
Sep 11, 2026 William John Sibold S Open-market sale 761 $544.83 $414.6K SEC filing ↗
Sep 11, 2026 William John Sibold S Open-market sale 1,539 $544.02 $837.2K SEC filing ↗
Sep 11, 2026 William John Sibold S Open-market sale 1,202 $542.60 $652.2K SEC filing ↗
Sep 11, 2026 William John Sibold S Open-market sale 368 $541.64 $199.3K SEC filing ↗
Sep 11, 2026 William John Sibold S Open-market sale 687 $540.59 $371.4K SEC filing ↗
Sep 11, 2026 William John Sibold S Open-market sale 160 $537.62 $86.0K SEC filing ↗
Sep 11, 2026 William John Sibold S Open-market sale 218 $535.94 $116.8K SEC filing ↗
Sep 11, 2026 William John Sibold S Open-market sale 106 $534.06 $56.6K SEC filing ↗
Sep 11, 2026 William John Sibold S Open-market sale 60 $533.09 $32.0K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 160 $542.55 $86.8K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 362 $541.65 $196.1K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 505 $540.19 $272.8K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 215 $539.03 $115.9K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 520 $538.30 $279.9K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 640 $537.17 $343.8K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 1,040 $536.11 $557.6K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 644 $535.27 $344.7K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 396 $534.20 $211.5K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 512 $533.09 $272.9K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 368 $531.99 $195.8K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 522 $530.23 $276.8K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 347 $529.27 $183.7K SEC filing ↗
Sep 9, 2026 William John Sibold S Open-market sale 131 $527.88 $69.2K SEC filing ↗
Aug 17, 2026 Shannon T Kelley S Open-market sale 664 $514.97 $341.9K SEC filing ↗

From SEC Form 4 filings. Every row links to the filing it came from. How we calculate this.

What a Form 4 is

The report an officer, director or large shareholder must file after trading their own company’s stock.

Corporate ownership links — 4 filers hold a position

Who owns MADRIGAL PHARMACEUTICALS, INC.

Each row is one filer naming this company.

Funds, trusts and other companies file the same ownership forms that executives do. Everything below is taken from those filings, with the position exactly as the filing states it.

Do not add these figures together. 4 of the positions below were reported on filings shared by several filers at once.

Why the same shares appear twice

On a joint filing every named filer is listed against the whole position, so the same block of stock appears under each name. Those rows are marked joint.

Filers holding a position in MADRIGAL PHARMACEUTICALS, INC.

Funds, trusts and companies that disclose an ownership position in MADRIGAL PHARMACEUTICALS, INC..
Owner Reported role Shares Filed
667, L.P. Director,Other,TenPercentOwner 1,947,968 joint
Baker Bros. Advisors (GP) LLC Director,Other,TenPercentOwner 1,947,968 joint
BAKER BROS. ADVISORS LP Director,Other,TenPercentOwner 1,947,968 joint
Baker Brothers Life Sciences LP Director,Other,TenPercentOwner 1,947,968 joint

See the full ownership map — every entity that files as an owner of a US public company.

Subsidiaries — 3 legal entities

Subsidiaries of MADRIGAL PHARMACEUTICALS, INC.

3 legal entities named in the subsidiary exhibit filed with this company’s most recent 10-K. . Filing on SEC.gov.

This is not the full list. SEC rules only require a company to name its significant subsidiaries.

What that leaves out

Smaller entities are left out of the exhibit entirely. A short list here means a short exhibit — it does not mean the company owns nothing else. Nothing on this page is inferred: every name below is copied from the filing.

Subsidiaries MADRIGAL PHARMACEUTICALS, INC. names in its most recent annual report, with the place each one is organised.
Subsidiary Organised in
Madrigal Pharmaceuticals B.V. Netherlands
Madrigal Pharmaceuticals Deutschland GmbH Germany
Madrigal Pharmaceuticals GmbH Switzerland
What counts as a subsidiary

A subsidiary is a separate legal entity this company controls; it is not the same thing as a brand, a division or an office. These entities do not file with the SEC in their own right, so there is no separate page to open for them.

Think a number here is wrong? Open the linked filing and compare — how to report it.

Sources and technical notes

Every figure on this page comes from filings to the U.S. SEC via EDGAR. Nothing here is estimated, and nothing is taken from press coverage or company websites.

Share count: cover page of the latest filing (dei:EntityCommonStockSharesOutstanding), taken from MADRIGAL PHARMACEUTICALS, INC.’s own filings and multiplied by our closing price. Full method.

What that share count means

the share count the company itself prints on the cover of its most recent filing, as of the date it signed that filing.

We do not take a market cap from a data vendor, and we do not estimate one: the figure is a share count from MADRIGAL PHARMACEUTICALS, INC.’s own SEC filings multiplied by the closing price we hold for the same stock.